KR20210002050A - Vaccine composition for foot and mouth disease virus - Google Patents

Abstract

The present invention relates to a polypeptide, a polynucleotide, and a plasmid involved in the production of an immune response against foot-and-mouth disease virus, and a vaccine composition comprising the same. Also, the present invention relates to a method for producing an immune response against foot-and-mouth disease virus in individuals. Also, the present invention relates to a polypeptide, a polynucleotide, and a plasmid involved in the production of an immune response against foot-and-mouth disease virus, and a pharmaceutical composition for the prevention of foot-and-mouth disease comprising the same. In addition, the present invention relates to a method for preventing foot-and-mouth disease in individuals.

Description

Foot-and-mouth disease virus vaccine composition TECHNICAL FIELD

The present invention relates to polypeptides, polynucleotides, plasmids, and vaccine compositions containing them, which are involved in generating an immune response against foot-and-mouth disease virus. In addition, the present invention relates to a method of generating an immune response against foot-and-mouth disease virus in a subject. In addition, the present invention relates to a polypeptide, a polynucleotide, a plasmid involved in the generation of an immune response against a foot-and-mouth disease virus, and a pharmaceutical composition for preventing foot-and-mouth disease containing them. Further, the present invention relates to a method for preventing foot-and-mouth disease in a subject.

Foot and Mouth Disease (FMD) is a viral disease in the mouth, nose, nipples, and hoofs, including livestock (cows, pigs, sheep, goats, deer, etc.) and various wild animals. It is characterized by the formation of blisters. FMD is a very contagious disease with a mortality rate of 40% or more, which has a great social and economic impact. For this reason, the International Waters Office (OIE) classifies and manages FMD as a Class A disease, and most countries also designate and manage it as a type 1 livestock infectious disease. In addition, the outbreak of FMD, which has been devastating economically, has occurred over the past decade on almost every continent.

Foot and Mouth Disease Virus (FMDV) is a single-stranded positive RNA virus belonging to the genus Appdovirus of the Picornavirus family, and has a strong invasion power and a wide range of infections. The incubation period varies from animal to animal, but is short, about 6-10 days. In addition, since the virus is already excreted outside the body before clinical symptoms appear, transmission can easily occur. FMDV is transmitted through the respiratory, digestive, and genitals. In particular, viruses released into the respiratory tract can be transmitted through the air for up to 250 km.

FMDV can be classified into 7 serotypes (O, A, C, SAT1, SAT2, SAT3, Asia1) according to the sequence of the coding region of VP1, which is the most mutated among structural protein gene regions and is important for determining immunogenicity such as formation of neutralizing antibodies. have. In addition, each serotype can be classified into up to 80 subtypes according to genetic characteristics.

Since type O serotype FMD is most common in Asia, Southeast Asia, and Europe, including Korea, the type O serotype FMD vaccine has been actively studied and inoculated. However, the type O serotype FMD vaccine that has been studied so far has not been effective in protecting against foot-and-mouth disease virus recently occurring in Asia including Korea. Accordingly, there is a great need for the development of a vaccine against a new foot-and-mouth disease virus type O serotype.

On the other hand, since foot-and-mouth disease mainly occurring in Korea was serotype O virus, preparations for type A virus were insufficient, and the situation became serious as foot-and-mouth disease in Yeoncheon, Korea was found to be serotype A virus in February 2017. .

In addition, foot-and-mouth disease virus type Asia1 is known to have relatively weak pathogenicity among foot-and-mouth disease serotypes, but in East Asia, Asia1 type has been continuously occurring since the outbreak of Asia1 type foot and mouth disease in China in 2005 (Hammond J. 2009. OIE/FAO World Reference Laboratory report , January-March 2009, Foot-and-mouth Diasease.World Reference Laboratory, Pirbright: 1-33). These are viruses belonging to the genotype Group V and have been found to be genetically related to viruses isolated in India (Park, Jong-Hyun et al., 2008a, "Recent Global Outbreak Characteristics and Molecular Epidemiology of Foot-and-mouth Disease", Journal of the Korean Society of Veterinary Public Health). Considering the outbreak of foot-and-mouth disease in the surrounding regions of Korea, it is necessary to prepare for the situation in which the Asia1 foot-and-mouth disease virus will enter Korea in addition to types A and O.

Vaccines against a specific serotype virus do not immunize against other serotype viruses, and there are cases where the DNA sequence of two strains belonging to the same serotype differs by up to 30% of the total genes. As such, FMDV has several serotypes and subtypes, so foot-and-mouth disease vaccines have to be applied individually for each serotype. In addition, it is difficult to produce an effective vaccine because there are many variations within one serotype. In addition, there is a disadvantage that immunity is maintained for only a few months even if the foot-and-mouth disease vaccine is given.

As mentioned above, since a vaccine against one serotype of foot-and-mouth disease does not immunize against another serotype, a bivalent or more multivalent vaccine should be inoculated to prevent the simultaneous appearance of two or more types of viruses. Accordingly, there is a need for a multivalent vaccine capable of generating antigens against two or more serotypes with a single vaccination.

One object of the present invention is to provide a polypeptide capable of generating an immune response against foot-and-mouth disease virus and a polynucleotide encoding the same.

Another object of the present invention is to provide a plasmid capable of generating an immune response against foot-and-mouth disease virus.

Another object of the present invention is to provide a vaccine composition against foot-and-mouth disease virus.

Another object of the present invention is to provide a method for generating an immune response against foot-and-mouth disease virus in a subject.

Another object of the present invention is to provide a pharmaceutical composition for preventing foot-and-mouth disease in an individual.

Another object of the present invention is to provide a method of preventing foot-and-mouth disease in a subject.

In order to achieve the above object, an aspect of the present invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more homology thereto. The amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more sequence homology thereto may be a sequence corresponding to the VP1 region of foot-and-mouth disease virus O type.

As used herein, the term "homology" refers to the degree to which a given polypeptide sequence or polynucleotide sequence is matched and may be expressed as a percentage. In the present specification, a given polypeptide sequence and its homologous sequence having the same or similar activity as "% homology" are indicated. The homology is, for example, using standard software that calculates parameters such as score, identity, and similarity, for example, BLAST 2.0, or hybridization used under defined stringent conditions. It can be confirmed by comparing the sequences by experimentation, and the appropriate hybridization conditions to be defined can be determined by methods well known to those skilled in the art.

The amino acid sequence of SEQ ID NO: 1 is an amino acid sequence obtained by recombining VP1s of serotype O foot-and-mouth disease virus recently generated in Asia. A polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more homology thereto can effectively function as an antigen capable of generating an immune response against foot-and-mouth disease virus, particularly, type O foot-and-mouth disease virus.

One aspect of the present invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more homology thereto, and the amino acid sequence of proteins VP2 to VP4 of foot-and-mouth disease virus.

In the polypeptide, the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more homology thereto may be sequentially linked with amino acid sequences corresponding to proteins VP2, VP3 and VP4, preferably derived from foot-and-mouth disease virus. For example, the VP4 region amino acid sequence-VP2 region amino acid sequence-VP3 region amino acid sequence-may be linked in the sequence of the amino acid sequence of SEQ ID NO: 1. The amino acid sequence of the VP2 to VP4 proteins may preferably be derived from foot-and-mouth disease virus, particularly O-type foot-and-mouth disease virus.

Additional amino acid sequences may be included between each amino acid sequence. For example, an amino acid sequence of a furin cleavage site may be included between the sequence of each VP region. For example, the purine cleavage site may be an RGRKRRS sequence, or an AGGGGAAGAAAGAGGAGAAGC sequence, or an AGGGGACGCAAGAGGCGCTCA sequence.

In addition, the polypeptide may further include a Kozak sequence, an IgE leader sequence and/or a 2A amino acid sequence. For example, the polypeptide may include an IgE leader sequence-VP4 region amino acid sequence-VP2 region amino acid sequence-VP3 region amino acid sequence-amino acid sequence of SEQ ID NO: 1-2A amino acid sequence (preferably included in the above order) . In this case, preferably, an amino acid sequence of a purine cleavage site may be further included between the sequences of each region. The 2A amino acid sequence may be, for example, an amino acid sequence corresponding to the ACCCTGAACTTCGACCTCCTCAAACTGGCTGGCGATGTGGAAAGCAATCCTGGATGATAA nucleotide sequence.

In addition, the polypeptide may include a polypeptide that generates an immune response against two or more different serotype foot and mouth disease viruses. For example, the polypeptide produces an immune response against 2, 3, 4, 5, 6 or 7 selected from O, A, C, SAT1, SAT2, SAT3 and Asia1 serotype foot-and-mouth disease virus. It may include a polypeptide.

As a specific example of a divalent vaccine, the polypeptide has an IgE leader sequence-FMDV type A VP4 region-FMDV A type VP2 region-FMDV A type VP3 region-FMDV A type VP1 region-FMDV O type VP4 region- FMDV O type VP2 region-FMDV O type VP3 region-FMDV O type VP1 region-2A amino acid sequence. The amino acid sequence of the purine cleavage site may further be included between the sequence of each region, for example, the IgE leader sequence-the VP4 region of FMDV A type-the purine cleavage site-the VP2 region of FMDV A type-the purine cleavage site-FMDV A VP3 area of type-Purine cleavage site-FMDV type A VP1 area-Purine cleavage site-FMDV O type VP4 area-Purine cleavage site-FMDV O type VP2 area-Purine cleavage site-FMDV O type VP3 area-Purine Cleavage site-FMDV type O VP1 region-Purine cleavage site-2A amino acid sequence. This type of divalent vaccine can exhibit immunity against type O and type A foot-and-mouth disease viruses.

As a specific example of a trivalent vaccine, the polypeptide has an IgE leader sequence-FMDV type A VP4 region-FMDV A type VP2 region-FMDV A type VP3 region-FMDV A type VP1 region-FMDV O type VP4 region- FMDV O type VP2 area-FMDV O type VP3 area-FMDV O type VP1 area-FMDV Asia1 type VP4 area-FMDV Asia1 type VP2 area-FMDV Asia1 type VP3 area-FMDV Asia1 type VP1 area-2A It may contain an amino acid sequence. The amino acid sequence of the purine cleavage site may further be included between the sequence of each region, for example, the IgE leader sequence-the VP4 region of FMDV A type-the purine cleavage site-the VP2 region of FMDV A type-the purine cleavage site-FMDV A VP3 area of type-Purine cleavage site-FMDV type A VP1 area-Purine cleavage site-FMDV O type VP4 area-Purine cleavage site-FMDV O type VP2 area-Purine cleavage site-FMDV O type VP3 area-Purine Cleavage site-FMDV O type VP1 area-Purine cleavage site-FMDV Asia1 type VP4 area-Purine cleavage site-FMDV Asia1 type VP2 area-FMDV Asia1 type VP3 area-FMDV Asia1 type VP1 area-Purine cleavage site- 2A amino acid sequence. This type of trivalent vaccine can show immunity against type O, type A and Asia1 foot-and-mouth disease virus.

Preferably, in the bivalent or trivalent vaccine, the VP1 region of FMDV O type comprises the amino acid sequence of SEQ ID NO: 1.

Preferably, in the bivalent or trivalent vaccine, FMDV type A is a sequence disclosed in another patent application No. 10-2018-0149242 of the present applicant (application date: November 28, 2018).

As an example, in the bivalent or trivalent vaccine, the VP1 region of FMDV type A includes the amino acid sequence of SEQ ID NO: 85 or 86. Here, SEQ ID NOs: 85 and 86 are recombinant sequences corresponding to the VP1 region of foot-and-mouth disease virus A serotype.

As another example, in the bivalent or trivalent vaccine, the VP4 region of FMDV type A-VP2 region of FMDV type A-VP3 region of FMDV type A is the amino acid sequence of SEQ ID NO: 87 or comprises the amino acid sequence of SEQ ID NO: 87. I can. Here, the amino acid sequence of the purine cleavage site may be further included between each VP region.

One aspect of the present invention provides a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having 90% or more homology thereto.

Alternatively, another aspect of the present invention provides a polynucleotide encoding the amino acid sequence of SEQ ID NO: 1. The polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may be the nucleotide sequence of SEQ ID NO: 2.

Alternatively, the polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may be a sequence in which the nucleotide sequence of SEQ ID NO: 2 is changed to a codon optimized for an animal to generate an immune response. The animals include all animals, such as pigs, cows, and sheep, as long as they may develop foot-and-mouth disease, and may preferably be pigs.

One aspect of the present invention provides a plasmid comprising a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having 90% or more homology thereto.

Another aspect of the present invention provides a plasmid comprising a polynucleotide encoding an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% homology to the sequence of SEQ ID NO: 1.

As used herein, the term "plasmid" refers to a DNA preparation containing a DNA sequence operably linked to a suitable regulatory sequence capable of expressing DNA in a suitable host. The plasmid can be a vector, a phage particle, or simply a potential genomic insert. In the present specification, the plasmid may be used interchangeably with a vector (or viral vector).

The plasmid may further include a nucleotide sequence encoding proteins VP2 to VP4 of foot-and-mouth disease virus. The nucleotide sequence encoding the VP2 to VP4 protein may preferably be derived from a foot-and-mouth disease virus, particularly an O-type foot-and-mouth disease virus.

In the plasmid, a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having 90% or more homology thereto may be linked to the nucleotide sequence encoding the VP2 to VP4 protein of foot and mouth disease virus, preferably derived from foot and mouth disease virus. It can be sequentially linked with a nucleotide sequence encoding a VP2, VP3 and VP4 protein. For example, the plasmid may include a polynucleotide linked in the sequence of the nucleotide sequence of the VP4 region-the nucleotide sequence of the VP2 region-the nucleotide sequence of the VP3 region-the nucleotide sequence of SEQ ID NO: 2 (5'->3' basis). have.

Additional nucleotide sequences may be included between the nucleotide sequences of each region. The additional nucleotide sequence may be a nucleotide sequence corresponding to the purine cleavage site region. For example, the purine cleavage site may be an AGGGGAAGAAAGAGGAGAAGC sequence, or an AGGGGACGCAAGAGGCGCTCA sequence.

As a preferred example, the plasmid may contain the nucleotide sequence of SEQ ID NO: 3.

In addition, the plasmid may further include a Kozak sequence, an IgE leader sequence and/or a 2A sequence. For example, the plasmid may include an IgE leader sequence-a nucleotide sequence of the VP4 region-a nucleotide sequence of the VP2 region-a nucleotide sequence of the VP3 region-a nucleotide sequence of SEQ ID NO: 2-2A nucleotide sequence (preferably the above sequence Inclusive). The 2A nucleotide sequence may be, for example, ACCCTGAACTTCGACCTCCTCAAACTGGCTGGCGATGTGGAAAGCAATCCTGGATGATAA nucleotide sequence.

In addition, the plasmid may contain a polynucleotide that generates an immune response against two or more different serotype foot-and-mouth disease viruses. For example, the polynucleotide generates an immune response against 2, 3, 4, 5, 6 or 7 selected from O, A, C, SAT1, SAT2, SAT3 and Asia1 serotype foot and mouth disease viruses. It may include a polynucleotide.

As a specific example of a divalent vaccine, the polynucleotide has an IgE leader sequence-FMDV A type VP4 region-FMDV A type VP2 region-FMDV A type VP3 region-FMDV A type VP1 region-FMDV O type VP4 region -FMDV O type VP2 region-FMDV O type VP3 region-FMDV O type VP1 region-2A base sequence may be included. Between the sequences of each region may further include a nucleotide sequence of the purine cleavage site, for example, the IgE leader sequence-FMDV type A VP4 region-Purine cleavage site-FMDV A type VP2 region-Purine cleavage site-FMDV A VP3 area of type-Purine cleavage site-FMDV type A VP1 area-Purine cleavage site-FMDV O type VP4 area-Purine cleavage site-FMDV O type VP2 area-Purine cleavage site-FMDV O type VP3 area-Purine Cleavage site-FMDV O type VP1 region-Purine cleavage site-2A nucleotide sequence may be included. This type of divalent vaccine can exhibit immunity against type O and type A foot-and-mouth disease viruses.

As a specific example of a trivalent vaccine, the polynucleotide is an IgE leader sequence-FMDV A type VP4 region-FMDV A type VP2 region-FMDV A type VP3 region-FMDV A type VP1 region-FMDV O type VP4 region -VP2 area of FMDV O type-VP3 area of FMDV O type-VP1 area of FMDV Asia1 type-VP4 area of FMDV Asia1 type-VP2 area of FMDV Asia1 type-VP3 area of FMDV Asia1 type-FMDV Asia1 type VP1 area- It may contain the 2A nucleotide sequence. Between the sequences of each region may further include a nucleotide sequence of the purine cleavage site, for example, the IgE leader sequence-FMDV type A VP4 region-Purine cleavage site-FMDV A type VP2 region-Purine cleavage site-FMDV A VP3 area of type-Purine cleavage site-FMDV type A VP1 area-Purine cleavage site-FMDV O type VP4 area-Purine cleavage site-FMDV O type VP2 area-Purine cleavage site-FMDV O type VP3 area-Purine Cleavage site-FMDV O type VP1 area-Purine cleavage site-FMDV Asia1 type VP4 area-Purine cleavage site-FMDV Asia1 type VP2 area-FMDV Asia1 type VP3 area-FMDV Asia1 type VP1 area-Purine cleavage site- It may contain the 2A nucleotide sequence. This type of trivalent vaccine can show immunity against type O, type A and Asia1 foot-and-mouth disease virus.

Preferably, in the bivalent or trivalent vaccine, the VP1 region of FMDV O type comprises the amino acid sequence of SEQ ID NO: 1.

Preferably, in the bivalent or trivalent vaccine, FMDV type A is a sequence disclosed in another patent application No. 10-2018-0149242 of the present applicant (application date: November 28, 2018).

As an example, in the bivalent or trivalent vaccine, the VP1 region of FMDV type A includes a nucleotide sequence of SEQ ID NO: 88, 89 or 90. Here, SEQ ID NOs: 88, 89 and 90 are recombinant sequences corresponding to the VP1 region of foot-and-mouth disease virus A serotype, respectively. In particular, the nucleotide sequence of SEQ ID NO: 89 is an optimized nucleotide sequence of SEQ ID NO: 88 with a pig codon.

As another example, in the bivalent or trivalent vaccine, the VP4 region of FMDV type A-VP2 region of FMDV type A-VP3 region of FMDV type A is the nucleotide sequence of SEQ ID NO: 91 or comprises the nucleotide sequence of SEQ ID NO: 91 . Here, a base sequence of a purine cleavage site may be further included between each VP region.

As another example, in the bivalent or trivalent vaccine, the VP4 region of FMDV type A-VP2 region of FMDV type A-VP3 region of FMDV type A-VP1 region of FMDV type A is the base sequence of SEQ ID NO: 92 or SEQ ID NO: It contains the nucleotide sequence of 92. Here, a base sequence of a purine cleavage site may be further included between each VP region.

As another example, in the bivalent or trivalent vaccine, the VP4 region of FMDV Asia1 type-the VP2 region of FMDV type A-the VP3 region of FMDV type A-the VP1 region of FMDV type A is the nucleotide sequence of SEQ ID NO: 94 or SEQ ID NO: It contains the nucleotide sequence of 94. Here, a base sequence of a purine cleavage site may be further included between each VP region.

Another aspect of the present invention provides a foot-and-mouth disease vaccine composition comprising the polypeptide of the present invention, the polynucleotide of the present invention, or the plasmid of the present invention.

In the foot-and-mouth disease vaccine composition, the polypeptide, the polynucleotide, and the plasmid are as described above unless otherwise stated.

The term "vaccine" is a biological preparation containing an antigen that gives immunity to an individual, and refers to an immunogen or an antigenic substance that gives immunity to a living body by administration to humans or animals, for example by injection or oral administration, to prevent infection.

The vaccine may be a DNA vaccine. The term "DNA vaccine" refers to a vaccine that causes an immune response by artificially replicating some of the genes such as pathogens or viruses and then administering the same. These DNA vaccines have various advantages over existing protein vaccines. i) First of all, since they can be synthesized only with the genetic information of the pure target pathogen antigen, there is no need to directly deal with dangerous pathogens, and ii) genes necessary for inducing toxicity. It has various advantages, such as being able to develop vaccines in response to various infectious diseases that occur rapidly due to its simplicity consisting of only plasmid DNA because it uses only some of them. do.

The foot-and-mouth disease vaccine composition may preferably have a protective immunity against foot-and-mouth disease virus, in particular, type O foot-and-mouth disease virus.

The vaccine composition of the present invention may contain a veterinary acceptable carrier. The term "veterinarily acceptable carrier" includes any and all solvents, dispersion media, coatings, adjuvants, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like. Carriers, excipients, and diluents that may be included in the vaccine composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, glycerin, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose. , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils. In addition, the composition for a vaccine of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., and sterile injectable solutions according to a conventional method. In the case of formulation, it can be prepared using diluents or excipients such as generally used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Particularly preferably, poly-L-Glutamic acid may be used to aid in stabilization.

The vaccine composition may be injected into a subject in various forms. "Injection" may be performed by any one method selected from the group consisting of subcutaneous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, nasal administration, intravenous administration, transdermal administration, and oral administration.

The vaccine composition may include one or more adjuvants to improve or strengthen the immune response. Suitable adjuvants include peptides, aluminum hydroxides, aluminum phosphates, aluminum oxides and compositions consisting of mineral or vegetable oils such as Marcol 52 and one or more emulsifiers or surface active substances such as resolcecitin, polyvalent cations, polyanions, etc. .

One aspect of the present invention provides a multivalent vaccine composition against two or more serotypes of foot-and-mouth disease virus.

Foot-and-mouth disease virus having protective immunity of the vaccine composition may be two or more selected from O, A, C, SAT1, SAT2, SAT3 and Asia1 serotype foot-and-mouth disease virus, for example, 2, 3, 4, 5, It can be 6 or 7. As a specific example, the foot-and-mouth disease virus having protective immunity in the vaccine composition may be type O and type A, in which case the vaccine composition acts as a divalent vaccine composition. As another specific example, the foot-and-mouth disease virus having protective immunity in the vaccine composition may be type O, type A, and type Asia1, in which case the vaccine composition acts as a divalent vaccine composition.

One aspect of the present invention provides a method of generating an immune response against a foot-and-mouth disease virus in an individual, comprising administering to the individual the vaccine composition of the present invention.

In the method for generating an immune response, the vaccine composition is as described above unless otherwise stated.

As used herein, the term "immune response" refers to the activation of the host's immune system, eg, the mammalian's immune system in response to introduction of an antigen. The immune response can be in the form of a cellular response or a humoral response, or both.

The term "individual" as used herein refers to animals including humans, and may be, for example, mammals, cows, more specifically pigs, cows, sheep, and the like. The term “subject” may be used interchangeably with a subject.

In the method for generating an immune response, the vaccine composition of the present invention may contain an effective amount of an active ingredient, that is, a total recombinant polypeptide, a recombinant polynucleotide, or a plasmid containing the same, together with a pharmaceutically acceptable carrier and adjuvant. The term “effective amount” means that a component of the vaccine is an amount sufficient to induce a specific immune response against foot-and-mouth disease virus type O in the vaccinated animal. The effective amount can be easily determined by a person skilled in the art, for example, through routine experimentation in animals.

The administration may be administered by any route suitable for administration of the DNA vaccine, for example, by subcutaneous, intramuscular, intraperitoneal or intravenous injection.

Preferably, the foot-and-mouth disease virus is an O-type foot-and-mouth disease virus.

Another aspect of the present invention provides a method for preventing foot-and-mouth disease, preferably type O foot-and-mouth disease, in a subject, comprising administering to the subject the vaccine composition of the present invention.

Another aspect of the present invention provides a pharmaceutical composition for preventing foot-and-mouth disease, preferably O-type foot-and-mouth disease, comprising the polypeptide, polynucleotide or plasmid according to the present invention.

In the method for preventing foot-and-mouth disease and the pharmaceutical composition for preventing foot-and-mouth disease according to the present invention, each term has the same meaning as described above unless otherwise noted.

The term "prevention" as used in the present invention means all actions in which foot-and-mouth disease is suppressed or delayed by administration of the composition according to the present invention.

The foot-and-mouth disease virus vaccine composition according to the present invention can provide a DNA vaccine composition exhibiting high immunogenicity against foot-and-mouth disease virus. Accordingly, when the vaccine composition of the present invention is administered, antibodies against foot-and-mouth disease virus are produced at a remarkably high level in the inoculated individual, and thus an immune response is effectively exhibited. In particular, it has excellent protective immune response against foot-and-mouth disease type O virus, especially foot-and-mouth disease type O virus, which has recently occurred in Asia.

Therefore, when the foot-and-mouth disease virus vaccine composition according to the present invention is administered to an individual such as pigs or cows, it is possible to achieve excellent preventive effects against foot-and-mouth disease.

In addition, the foot-and-mouth disease vaccine composition according to the present invention may be used in combination with other serotype foot-and-mouth disease virus vaccines or inhibitors, or other serotype foot-and-mouth disease treatment or prevention agents. Alternatively, the foot-and-mouth disease virus vaccine composition according to the present invention may be constructed and used to prevent two or more serotype foot-and-mouth disease as a multivalent vaccine.

1 shows a recombinant VP1 amino acid sequence (SEQ ID NO: 1) prepared by substituting some of the amino acids of the existing serotype O FMD DNA vaccine VP1.
2 shows a recombinant VP1 nucleotide sequence (SEQ ID NO: 2) prepared by substituting a part of the amino acid of the existing serotype O FMD DNA vaccine VP1.
Figure 3 is a schematic diagram showing the process of replacing the existing serotype O FMD DNA vaccine VP1 region with a new recombinant VP1 nucleotide sequence.
Figure 4 specifically shows the partial sequence and site of the PLS-FMD-O DNA vaccine.
5 shows the results of analysis of the antibody formation effect according to the vaccine administration of the present invention in mice by SPC ELISA.
6 is an illustration of a bivalent DNA vaccine according to the present invention, which is a multivalent vaccine showing effects against foot-and-mouth disease type A and type O.
7 shows the results of analyzing the antibody formation effect by administration of the divalent vaccine of the present invention in mice by SPC ELISA.
8 is an illustration of the trivalent DNA vaccine according to the present invention, which is a multivalent vaccine showing effects against foot-and-mouth disease type A, type O, and type Asia1.
9 shows the results of analyzing the antibody formation effect by administration of the trivalent vaccine of the present invention in mice by SPC ELISA.

Hereinafter, the present invention will be described in more detail by examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited by these examples.

Example 1: Sequence analysis of foot-and-mouth disease virus serotype O

From the website of the World Reference Laboratory for Foot-and-Mouth Disease (WRLFMD), the ME report (Molecular epidemiology report) on the VP1 region of the serotype O foot-and-mouth disease virus recently developed in Asia was investigated.

The VP1 region of foot-and-mouth disease virus has the most mutation among the P1 structural protein gene regions of foot-and-mouth disease virus and is an important site for determining immunogenicity such as formation of neutralizing antibodies.

The survey targets were Bangladesh, Bhutan, Cambodia, China, Hong Kong, Indonesia, India, Japan, Laos, Malaysia, Mongolia, Myanmar, Nepal, Philippines, Russia, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, and Vietnam in a total of 21 countries.

(1) Cambodia

year Virus name Accession %Id Topotype Lineage 2016 VIT/47/2013 KY492072 96.7% ME-SA PanAsia VIT/46/2013 KX944731 96.7% ME-SA PanAsia VIT/51/2013 KY492073 96.4% ME-SA PanAsia VIT/12/2014 KY492074 96.5% ME-SA PanAsia VIT/13/2013 KX944715 96.5% ME-SA PanAsia VIT/15/2013 KX944717 96.5% ME-SA PanAsia VIT/32/2013 KX944725 96.5% ME-SA PanAsia 2015 CAM/01/2010 KR401196 95.7% ME-SA PanAsia CAM/03/2010 KR401197 95.7% ME-SA PanAsia VIT/20/2010 KR401207 95.7% ME-SA PanAsia

(2) China

year Virus name Accession %Id Topotype Lineage 2018 GZSD/CHA/2018 MG840803 100% CATHAY MYA/9/2017 MG972523 97.5% ME-SA Ind-2001 2017 XJBC/CHA/2017 KY696708 100% ME-SA Ind-2001 XJPS/CHA/2017 KY696707 100% ME-SA Ind-2001 2016 SCGH/CHA/2016 KX161429 100% CATHAY 2013 HN/CHA/HK212/2013 KU204893 100% CATHAY GD/CHA/JH12/2013 KU204894 100% CATHAY

(3) Hong Kong

year Virus name Accession %Id Topotype Lineage 2015 O/HKN/1/2013 KM243172 96.7% CATHAY 2014 HKN/3/2011 KM243166 97.5% CATHAY HKN/4/2011 KM243165 97.3% CATHAY HKN/26/2010 KM243164 96.7% CATHAY

(4) Indonesia: Declared FMD free in 1986

(5) Japan

year Virus name Accession %Id Topotype Lineage 2010 O/JPN/MZ1/2010 AB618503 100% SEA Mya-98 O/TZ/CHA/2010 HQ652081 99.5% SEA Mya-98 O/CHA/31/2010 JF792356 99.3% SEA Mya-98 O/BY/CHA/2010 JN998085 99.2% SEA Mya-98 O/HKN/7/2010 JQ070303 99.2% SEA Mya-98

(6) Laos

year Virus name Accession %Id Topotype Lineage 2016 MYA/2496/2015 KY399470 ME-SA Ind-2001d 2015 IND189/2013 KM264361 98.6% ME-SA Ind-2001d IND205/2013 KM264362 98.4% ME-SA Ind-2001d UAE/2/2014 KM921878 98.4% ME-SA Ind-2001d

(7) Malaysia

year Virus name Accession %Id Topotype Lineage 2016~2018 Zabaikalskiy/3/RUS/2016 MG972584 99.2% ME-SA Ind-2001 SKR/1/2017 MG972599 99.1% ME-SA Ind-2001 Zabaikalskiy/2/RUS/2016 MG972583 99.1% ME-SA Ind-2001 BAN/GKa-236(pig)/2015 KX712091 99.1% ME-SA Ind-2001

(8) Mongolia

year Virus name Accession %Id Topotype Lineage 2017~2018 VIT/05/2011 KT153087 99.4% ME-SA PanAsia VIT/5/2011 KR401211 99.7% ME-SA PanAsia MAY/2/2014 KY322671 99.4% SEA Mya-98 MOG/BU/2-7/2015 LC320038 98.9% ME-SA Ind-2001 Zabaikalskiy/3/RUS/2016 MG972584 98.7% ME-SA Ind-2001 XJBC/CHA/2017 KY696708 98.7% ME-SA Ind-2001 XJ/CHA/2017 MF461724 98.7% ME-SA Ind-2001 VIT/20/2016 MG972619 98.6% ME-SA Ind-2001 VIT/13/2013 KX944715 98.1% ME-SA PanAsia

(9) Myanmar

year Virus name Accession %Id Topotype Lineage 2017 MYA/9/2017 MG972523 100% ME-SA Ind-2001 MYA/6/2017 MG972521 100% ME-SA Ind-2001 MYA/19/2017 MG972529 100% ME-SA Ind-2001 MYA/1/2017 MG972517 100% SEA Mya-98 MYA/4/2017 MG972519 100% SEA Mya-98 MYA/5/2017 MG972520 100% SEA Mya-98 2016 NEP/6/2016 KY449054 99.2% ME-SA Ind-2001 NEP/17/2015 KY449050 99.2% ME-SA Ind-2001 NEP/19/2015 KY449051 99.2% ME-SA Ind-2001

(10) Philippines: No recorded FMD outbreaks since December 2005

(11) Russia

year Virus name Accession %Id Topotype Lineage 2018~2019 XJPS/CHA/2017 KY696707 97% ME-SA Ind-2001 2016 Zabaikalskiy/1/RUS/2016 MG983720 100% ME-SA Ind-2001d Zabaikalskiy/2/RUS/2016 MG972583 100% ME-SA Ind-2001d Zabaikalskiy/3/RUS/2016 MG972584 100% ME-SA Ind-2001d Zabaikalskiy/4/RUS/2016 MG972585 100% ME-SA Ind-2001d

(12) Singapore: FMD free, eradicated in 1973

(13) Korea

year Virus name Accession %Id Topotype Lineage 2019 XJPS/CHA/2017 KY696707 97% ME-SA Ind-2001 2017 SKR/1/2017 MG972599 100% ME-SA Ind-2001 SKR/2/2017 MG972600 100% ME-SA Ind-2001 170205/SKR/2017 SKR/1,2/2017 100% 100% ME-SA Ind-2001 Zabaikalskiy/1/RUS/2016 MG983720 99.4% ME-SA Ind-2001 Zabaikalskiy/2/RUS/2016 MG972583 99.4% ME-SA Ind-2001

(14) Taiwan

year Virus name Accession %Id Topotype Lineage 2013 O/TAW/1/2009 KM243161 96.9% CATHAY O-TW-258-2009 GQ292740 96.9% CATHAY 2012 O/NC/CHA/2010 HQ652080 97.2% SEA Mya-98 O/HKN/1/2010 JQ070301 97% SEA Mya-98 O/VN/YB10/2010 HQ260720 96.7% SEA Mya-98

(15) Thailand

year Virus name Accession %Id Topotype Lineage 2017~2018 Zabaikalskiy/3/RUS/2016 MG972584 98.6% ME-SA Ind-2001 MYA/1/2017 MG972517 98.6% ME-SA Ind-2001 MYA/9/2017 MG972523 98.4% ME-SA Ind-2001 BAN/GKa-236(pig)/2015 KX712091 98.4% ME-SA Ind-2001 SKR/2/2017 MG972600 98.4% ME-SA Ind-2001 2016 TAI-269-2-2016 MG972602 ME-SA Ind-2001 TAI-225-2016R3 MG972601 ME-SA Ind-2001

(16) Vietnam

year Virus name Accession %Id Topotype Lineage 2016~2017 NEP/15/2015 MG972547 98.9% ME-SA Ind-2001 Zabaikalskiy/3/RUS/2016 MG972584 98.6% ME-SA Ind-2001 VIT/20/2016 MG972619 97.3% CATHAY VIT/13/2013 KX944715 96.7% ME-SA PanAsia VIT/8338/2017 MH891503 MYA/4/2017a MG972519 VIT/36/2013 KX944726 CATHAY

(17) Bangladesh

year Virus name Accession %Id Topotype Lineage 2009 BAN/1/2009 HQ630676 100% ME-SA Ind-2001

(18) Bhutan

year Virus name Accession %Id Topotype Lineage 2017~2018 NEP/2/2017 MG972582 99.8% ME-SA Ind-2001d NEP/36/2016 MG972578 99.8% ME-SA Ind-2001d UAE/1/2015 MG972605 98.9% ME-SA Ind-2001 BAN/TG/Ba-268/2015 KY077621 ME-SA Ind-2001d 2015~2016 BAN/NL/Lo-245/2015 KY077611 99.7% ME-SA Ind-2001d NEP/6/2016 KY449054 99.1% ME-SA Ind-2001d BAR/15/2015 MG972473 98.9% ME-SA Ind-2001d IND205/2013 KM264362 98.6% ME-SA Ind-2001d

(19) India: None

(20) Nepal

year Virus name Accession %Id Topotype Lineage 2017 NEP/2/2017 MG972582 100% ME-SA Ind-2001 NEP/1/2017 MG972581 100% ME-SA Ind-2001 NEP/7/2016 KY449055 100% ME-SA Ind-2001 BHU/18/2009 KM921822 94.5% ME-SA Ind-2001 2016 NEP/20/2016 MG972564 100% ME-SA Ind-2001 NEP/25/2016 MG972568 100% ME-SA Ind-2001 NEP/30/2016 MG972572 ME-SA Ind-2001

(21) Sri Lanka

year Virus name Accession %Id Topotype Lineage 2018 BAN/GKa-236(pig)/2015 KX712091 98.3% ME-SA Ind-2001 Zabaikalskiy/3/RUS/2016 MG972584 98.1% ME-SA Ind-2001 2016~2017 SRL/2/2014 MF947475 98.7% ME-SA Ind-2001d SRL/1/2014 MF947474 98.7% ME-SA Ind-2001d SRL/6/2014 MF947478 98.7% ME-SA Ind-2001d SRL/9/2014 MF947481 98.6% ME-SA Ind-2001d

From the result of the ME report, a virus strain having GeneBank No. in which nucleotide sequence information can be known from NCBI GeneBank was selected. As a result, a total of 81 virus strains were selected, and VP1 nucleotide sequences of these viruses were converted into amino acid sequences. SEQ ID NOs: 4 to 84 were assigned to the VP1 amino acid sequence of the selected virus.

Virus name VP1 amino acid sequence AB618503
(JPN/MZ1/2010)
(SEQ ID NO: 4) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPSHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLPNVRGDLVDLQVLAKKAQARRPELLVDLQVLAKKAQAR MF461724
(XJ/CHA/2017)
(SEQ ID NO: 5) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MF947474
(SRL/1/2014)
(SEQ ID NO: 6) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKARQRPELLYDLQVLAQKAQ MF947475
(SRL/2/2014)
(SEQ ID NO: 7) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVLLYDLQVLAQKAQRPELLTDLQVLAQKAQ MF947478
(SRL/6/2014)
(SEQ ID NO: 8) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKARQRPELLYDLQVLAQKAQ MF947481
(SRL/9/2014)
(SEQ ID NO: 9) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKARQRPELLYDLQVLAQKAQ MH891503
(VIT/8338/2017)
(SEQ ID NO: 10) TTATGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKKAQKARTY MG840803
(GZSD/CHA/2018)
(SEQ ID NO: 11) TTSAGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEQVNVLDLMQVPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPETALDNNTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASANNVRLPLLTDLHKAIKARKAIQKARK MG972473
(BAR/15/2015)
(SEQ ID NO: 12) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEVALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKAQRPELLYDLQVLAQKAQ MG972517
(MYA/1/2017)
(SEQ ID NO: 13) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972519
(MYA/4/2017)
(SEQ ID NO: 14) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARAQ MG972520
(MYA/5/2017)
(SEQ ID NO: 15) TTSTGETADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEVALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLLGDLQVLAQKAQART MG972523
(MYA/9/2017)
(SEQ ID NO: 16) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDVMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972521
(MYA/6/2017)
(SEQ ID NO: 17) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADKEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRVLLTDLQVLAQKARTY MG972529
(MYA/19/2017)
(SEQ ID NO: 18) TTSTGETADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEVALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLLGDLQVLAQKAQART MG972547
(NEP/15/2015)
(SEQ ID NO: 19) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972564
(NEP/20/2016)
(SEQ ID NO: 20) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRVLLTDLQVLAQKARTYQLPTDLQVLAQKA MG972568
(NEP/25/2016)
(SEQ ID NO: 21) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRVLLTDLQALKAIQKARTYQLPTDLQALKKAQ MG972572
(NEP/30/2016)
(SEQ ID NO: 22) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972578
(NEP/36/2016)
(SEQ ID NO: 23) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPENQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRGLLDLQVLAQKAKART MG972581
(NEP/1/2017)
(SEQ ID NO: 24) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPENQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRGLLDLQVLAQKAKART MG972582
(NEP/2/2017)
(SEQ ID NO: 25) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPENQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRGLLDLQVLAQKAKART MG972583
(Zabaikalskiy/2
/RUS/2016)
(SEQ ID NO: 26) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972584
(Zabaikalskiy/3
/RUS/2016)
(SEQ ID NO: 27) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972585
(Zabaikalskiy/4
/RUS/2016)
(SEQ ID NO: 28) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972599
(SKR/1/2017)
(SEQ ID NO: 29) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972600
(SKR/2/2017)
(SEQ ID NO: 30) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972601(TAI-225-2016R3)
(SEQ ID NO: 31) TTSTGESADPVTTTVENYGGETQAQRRQHTDVSFILDRFVKVTPKDQINVLDVMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRVLPLLTDLQVLAQKARTY MG972602(TAI-269-2-2016)
(SEQ ID NO: 32) TTSTGESADPVTTTVENYGGETQAQRRQHTDVSFILDRFVKVTPKDQINVLDVMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRVLPLLTDLQVLAQKARTY MG972605
(UAE/1/2015)
(SEQ ID NO: 33) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG972619
(VIT/20/2016)
(SEQ ID NO: 34) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEVALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY MG983720
(Zabaikalskiy/1/RUS/2016)
(SEQ ID NO: 35) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY GQ292740
(O-TW-258-2009)
(SEQ ID NO: 36) TTSAGESADPVTATVENYGGETQVQRRQHTDIAFILDRFVKVKPEDEVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPVAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDTSTNNVRGDLQKVAILLKAKTERRPAIQRMPSARKTERRPTLSFQNF HQ260720
(O/VN/YB10/2010)
(SEQ ID NO: 37) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPPHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLTNVRGLLVDLQVLAQKAQKARRPELLYNGDLQVLAQKAK HQ630676
(BAN/1/2009)
(SEQ ID NO: 38) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVAPGDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESDVTNVRLPLLTSYDLQVLAQKAQKARTY HQ652080
(NC/CHA/2010)
(SEQ ID NO: 39) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPPHTLVGALLRTATYYFADLEVAVKHKGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLTNVRGLLVDLQVLAQKAQKARRPELLVDLQVLAQKAQKA HQ652081
(TZ/CHA/2010)
(SEQ ID NO: 40) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPSHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLPNVRGDLVDLQVLAKKAQARRPELLVDLQVLAKKAQAR JF792356
(CHA/31/2010)
(SEQ ID NO: 41) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPSHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLPNVRGLLVDLQVLAQKAKARRPELLVDLQVLAQKAQKA JN998085
(BY/CHA/2010)
(SEQ ID NO: 42) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPSHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLPNVRGLLVDLQVLAQKAKARRPELLVDLQVLAQKAQKA JQ070301
(HKN/1/2010)
(SEQ ID NO: 43) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQAPPHTLVGALLRAATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNYKYAGAGGSLTNVRGDLQVLAKKKARPELLAVNYSAGKKAKARQ JQ07030
(HKN/7/2010)
(SEQ ID NO: 44) TTSTGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDSINVLDLMQTPPHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAGGSLPNVRGLLVDLQVLAQKAQKARRPELLVDLQVLAQKAQKA KM921822
(BHU/18/2009)
(SEQ ID NO: 45) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESDVTNVRLPLLTSYDLQVLAQKKARTY KM921878
(UAE/2/2014)
(SEQ ID NO: 46) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKAQRPELLYDLQVLAQKAQ KM243127
(PHI/1/2005)
(SEQ ID NO: 47) TTSAGESADPVTTTVENYGGETQTQRRQHTDIAFILDRFVKVKPKEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASTNNVRGDLQNFPSLAKKTERRPAILLQVLAKQKTERQL KM243128
(PHI/1/2005)
(SEQ ID NO: 48) TTSAGESADPVTTTVENYGGETQTQRRQHTDIAFILDRFVKVKPKEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPETALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASANNVRGDLQNFPSLAQKTERRPAILLQVLAKQKTERTL KM243131
(PHI/3/2005)
(SEQ ID NO: 49) TTSAGESADPVTTTVENYGGETQTQRRQHTDIAFILDRFVKVKPKEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASTNNVRGDLQNFPSLAKKTERRPAILLQVLAKQKTERQL KM243161
(TAW/1/2009)
(SEQ ID NO: 50) TTSAGESADPVTATVENYGGETQVQRRQHTDIAFILDRFVKVKPEDEVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPVAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDTSTNNVRGDLQKVAILLKAKTERRPAIQRMPSARKTERRPTLSFQNF KM243164
(HKN/26/2010)
(SEQ ID NO: 51) TTSAGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPETALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASNTVLLLLYDLKAIQKTARPELLYDLKLAQKTERK KM243165
(HKN/3/2011)
(SEQ ID NO: 52) TTSAGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASNTLPLLTSYDLKAIQKKATYRPELLYDLQLAQKAQ KM243166
(HKN/4/2011)
(SEQ ID NO: 53) TTSAGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASNTLPLLTSYDLKAIQKKATYRPELLYDLQLAQKAQ KM243172
(HKN/1/2013)
(SEQ ID NO: 54) TTSVGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEQVNVLDLMQVPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPEAALNNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASLLVNTDVRGDLQKAIPALLKDL KM264361
(IND189/2013)
(SEQ ID NO: 55) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKAQRPELLYDLQVLAQKAQ KM264362
(IND205/2013)
(SEQ ID NO: 56) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGESNVPNVRLLVELLYDLQVLAQKAQRPELLYDLQVLAQKAQ KR401196
(CAM/01/2010)
(SEQ ID NO: 57) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLTDLQVLAQKARTYQLPTDLQVLAQK KR401197
(CAM/03/2010)
(SEQ ID NO: 58) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLTDLQVLAQKARTYQLPTDLQVLAQK KR401207
(VIT/20/2010)
(SEQ ID NO: 59) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLTDLQVLAQKARTYQLPTDLQVLAQK KR401211
(VIT/5/2011)
(SEQ ID NO: 60) TTSTGESADPVTATVENYGGETQVRRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVVGDLQVLAKKATYQRPELLYVLAKKKAART KT153087
(VIT/05/2011)
(SEQ ID NO: 61) TTSTGESADPVTATVENYGGETQVRRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVVGDLQVLAKKATYQRPELLYVLAKKKAART KU204893
(HN/CHA/HK212/2013)
(SEQ ID NO: 62) TTSAGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEHVNVLDLMQIPAHTLVGALLRAATYYFSDLELAVKHEGDLTWVPNGAPETALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSNKYGDASANNIRGELLDLHVLAKKATYRPELLVYNGSNKYGDASANNIRGELLDLHVLAKAKERT KU204894
(GD/CHA/JH12/2013)
(SEQ ID NO: 63) TTSAGESADPVTTTVENYGGETQVQRRQHTDVAFILDRFVKVKPQEQVNVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPETALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSSKYGDASANNVRLPLLYDLHVLAKKNARPELLYDLHVLAKKAERT KX944715
(VIT/13/2013)
(SEQ ID NO: 64) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KX944717
(VIT/15/2013)
(SEQ ID NO: 65) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KX161429
(SCGH/CHA/2016)
(SEQ ID NO: 66) TTSAGESADPVTTTVENYGGETQAQRRQHTDVAFILDRFVKVKPQEQINVLDLMQIPAHTLVGALLRTATYYFSDLELAVKHEGDLTWVPNGAPEAALDNTTNPTAYHKEPLTRLALPYTAPHRVLATVYNGSNKKYGDTSANNVRLPLLATDLHVLAKKNAQRPELLYDLHVLAKKNAQ KX712091
(BAN/GKa-236(pig)/2015)
(SEQ ID NO: 67) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KX944725
(VIT/32/2013)
(SEQ ID NO: 68) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KX944726
(VIT/36/2013)
(SEQ ID NO: 69) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KX944731
(VIT/46/2013)
(SEQ ID NO: 70) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KY077611
(BAN/NL/Lo-245/2015)
(SEQ ID NO: 71) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKART KY077621
(BAN/TG/Ba-268/2015)
(SEQ ID NO: 72) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KY322671
(MAY/2/2014)
(SEQ ID NO: 73) TTSAGESADPVTATVENYGGETQVQRRHHTDVSFILDRFVKVTPKDQINVLDLMQTPSHTLVGALLRTATYYFADLEVAVKHEGDLTWVPNGAPETALENTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYAEGSLTNVRGLLDLQVLAQKAQKARRPLLYDLQVLAQKAQKA KY492072
(VIT/47/2013)
(SEQ ID NO: 74) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KY492073
(VIT/51/2013)
(SEQ ID NO: 75) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KY492074
(VIT/12/2014)
(SEQ ID NO: 76) TTSTGESADPVTATVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCRYGASPVTNVRVLLLLYDLQVLAQKAQRPELLYDLQVLAQKAQ KY399470
(MYA/2496/2015)
(SEQ ID NO: 77) TTSTGEYADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KY449050
(NEP/17/2015)
(SEQ ID NO: 78) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KY449051
(NEP/19/2015)
(SEQ ID NO: 79) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KY449054
(NEP/6/2016)
(SEQ ID NO: 80) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KY449055 (NEP/7/2016)
(SEQ ID NO: 81) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY KY696707
(XJPS/CHA/2017)
(SEQ ID NO: 82) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYLADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKKAQKARTY KY696708
(XJBC/CHA/2017)
(SEQ ID NO: 83) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPETALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY LC320038
(MOG/BU/2-7/2015)
(SEQ ID NO: 84) TTSTGESADPVTTTVENYGGETQVQRRQHTDVSFILDRFVKVTPKDQINVLDLMQTPAHTLVGALLRTATYYFADLEVAVKHEGNLTWVPNGAPEAALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGNCKYGEGAVTNVRLPLLTSYDLQVLAQKAQKARTY

Example 2: Preparation of a new DNA vaccine

The 81 amino acid sequences of SEQ ID NOs: 4 to 84 were aligned by Clustal/muscle. The consensus sequence of VP1 was derived based on the alignment results. As a result of comparing the consensus sequence thus derived with the sequence of the conventional serotype O type O FMD DNA vaccine (pGX9014), it was confirmed that there were a total of 5 amino acid mismatches.

In the VP1 region of the existing serotype O FMD DNA vaccine (pGX9014), 5 amino acids mismatched with the consensus sequence were substituted. 1 shows the amino acid sequence (SEQ ID NO: 1) of VP1 obtained through substitution. 2 shows the base sequence (SEQ ID NO: 2) of VP1 obtained through substitution.

A new FMD O type vaccine was prepared using the polynucleotide represented by the nucleotide sequence of SEQ ID NO: 2, and an overall schematic diagram is shown in FIG. 3. As can be seen in Figure 3, the Msc I site, the VP3 C-terminal site, the purine cleavage site, the recombinant VP1 site represented by the nucleotide sequence of SEQ ID NO: 2, the purine cleavage site, 2A, the recombinant nucleotides to which the Xho I sites are sequentially linked Ready. The specific sequence and each site of the recombinant nucleotide prepared as described above are shown in FIG. 4 and indicated by SEQ ID NO: 3. The DNA plasmid containing the nucleotide of SEQ ID NO: 3 was named "PLS-FMD-O".

E. coli with PLS-FMD-O was inoculated into 2.5 L of LB medium, and then cultured at 37°C overnight. Then, a plasmid was extracted from the cultured E. coli using EndoFree Plasmid Giga kit (QIAGEN, Cat#12391). The extracted plasmid was dissolved in Endo-free water and stored at -70°C. The stored plasmid was then used in an antibody formation experiment to confirm the vaccination effect in animals.

Example 3: Antibody formation effect of novel DNA vaccine

3.1. DNA vaccination

After dividing 15 mice C57BL/6 (8 weeks old, female) into 3 groups of 5 mice per group, the vaccine of the present invention, the existing vaccine, and mock plasmid inoculation were carried out 3 times every 2 weeks for each group as follows. I did. Inoculation was performed using an electroporation device (cellectra 2000), and a DNA vaccine was administered at a concentration of 30 μg/dog.

Group 1 (control)-Mock plasmid DNA

Group 2 (comparative group)-FMD DNA type O (pGX1414, existing vaccine)

Group 3 (experimental group)-FMD DNA type O (PLS-FMD-O, vaccine of the present invention)

Blood collection was performed using the orbital blood collection method before administration (week 0), after the second administration (week 4), and after the third administration (week 6). Serum was separated from the collected blood and stored at -80°C. The stored serum was dissolved and subjected to SPC (solid phase competition) ELISA analysis.

3.2. Antibody formation measurement-SPC ELISA assay

The SPC ELISA was performed using PrioCHECK FMDV Type A ELISA KIT (Prionics lelystad B.V/Netherlands), and the experimental method was performed according to the experimental protocol provided by the kit manufacturer.

The results are shown in FIG. 5. As can be seen in Figure 5, it was confirmed that the vaccine PLS-FMD-O of the present invention has a higher response inhibition (PI value) compared to the existing vaccine pGX1414. Here, the higher the response inhibition (PI value), the more specific antibodies to foot-and-mouth disease serotype O were produced. That is, the vaccine PLS-FMD-O of the present invention has a significantly greater amount of antibodies formed at the same time point compared to the existing vaccine pGX1414.

As described above, foot-and-mouth disease is highly contagious, and by excreting the foot-and-mouth disease virus to the outside of the body before clinical symptoms appear, not only does it easily occur between animals, but also has a very short incubation period. Therefore, in order to exhibit an effective function as a vaccine against foot-and-mouth disease, not only must the effect of inhibiting foot-and-mouth disease virus be excellent, but also the speed of antibody production against foot-and-mouth disease virus must be fast. When the vaccine according to the present invention is administered, not only has the inhibitory ability against foot-and-mouth disease virus significantly, but also the antibody production rate is significantly faster than that of the existing vaccine, so that the foot-and-mouth disease transmission can be inhibited early. It is very important in the vaccine against

Example 4: Preparation of a novel DNA bivalent vaccine

Bivalent DNA vaccines for foot-and-mouth disease type A and type O were prepared using the previously prepared recombinant sequences.

6 shows a specific example of the prepared bivalent vaccine. In the bivalent vaccine, the VP1 region of FMD A type may include the nucleotide sequence of SEQ ID NO: 88, 89 or 90, and the VP1 region of the FMD O type may include the nucleotide sequence of SEQ ID NO: 2.

The bivalent DNA vaccine for foot and mouth disease A and O type, prepared using the nucleotide sequence of SEQ ID NO: 89 as the FMD A type VP1 region and the nucleotide sequence of SEQ ID NO: 2 as the FMD O type VP1 region, is "PLS -FMD-A,O".

E. coli having PLS-FMD-A,O was inoculated into 2.5 L of LB medium, and then cultured at 37°C overnight. Then, a plasmid was extracted from the cultured E. coli using EndoFree Plasmid Giga kit (QIAGEN, Cat#12391). The extracted plasmid was dissolved in Endo-free water and stored at -70°C. The stored plasmid was then used in an antibody formation experiment to confirm the vaccination effect in animals.

Example 5: Antibody Formation Effect of Novel DNA Divalent Vaccine

5.1. DNA vaccination

After dividing 15 mice C57BL/6 (8 weeks old, female) into 3 groups of 5 mice per group, plasmid inoculation was performed 3 times at intervals of 2 weeks for each group. Group 2 was vaccinated with the combination of A-type monovalent vaccine and O-type monovalent vaccine, and Group 3 was vaccinated with type A and type O bivalent vaccines. Inoculation was performed using an electroporation device (cellectra 2000), and a DNA vaccine was administered at a concentration of 30 μg/dog.

Group 1 (control)-Mock DNA plasmid

Group 2 (Experimental group)-FMD type A plasmid + PLS-FMD-O

Group 3 (experimental group)-PLS-FMD-A,O

Blood collection was performed using the orbital blood collection method before administration (week 0), after the second administration (week 4), and after the third administration (week 6). Serum was separated from the collected blood and stored at -80°C. The stored serum was dissolved and subjected to SPC (solid phase competition) ELISA analysis.

5.2. Antibody formation measurement-SPC ELISA assay

The SPC ELISA was performed using PrioCHECK FMDV Type A ELISA KIT (Prionics lelystad B.V/Netherlands), and the experimental method was performed according to the experimental protocol provided by the kit manufacturer.

The results are shown in FIG. 7. As can be seen in FIG. 7, PLS-FMD-O exhibited a significantly higher level of response inhibition (PI value) even when inoculated with another serotype, that is, a foot-and-mouth disease vaccine in combination with another serotype. In addition, even when a single inoculation of the bivalent vaccine showed a significantly high level of response inhibition (PI value).

In particular, it can be seen that both O-type antibodies and A-type antibodies are formed early after vaccination, from which the recombinant O-type vaccine according to the present invention is inoculated with other serotypes or in combination with other serotypes. It can be seen that even if inoculated in the form of the prepared bivalent vaccine, it does not counteract the effect between different serotypes. Therefore, the recombinant O type vaccine according to the present invention has proven useful both as a monovalent vaccine and as a multivalent vaccine.

Example 6: Preparation of novel DNA trivalent vaccine

Trivalent DNA vaccines were prepared for foot-and-mouth disease type A, type O, and type Asia1 using the previously prepared recombinant sequences.

Figure 8 shows a specific example of the prepared trivalent vaccine. In the trivalent vaccine, the VP1 region of FMD A type may contain the nucleotide sequence of SEQ ID NO: 88, 89 or 90, and the VP1 region of the FMD O type may contain the nucleotide sequence of SEQ ID NO: 2, FMD Asia1 The VP1 region of the type may include a conventionally known nucleotide sequence.

Using the nucleotide sequence of SEQ ID NO: 89 as the VP1 region of FMD A type, the nucleotide sequence of SEQ ID NO: 2 as the VP1 region of FMD O type, and the nucleotide sequence of SEQ ID NO: 93 as the VP1 region of FMD Asia1 type The prepared, trivalent DNA vaccine against foot-and-mouth disease type A, type O and Asia1 was named "PLS-FMD-A,O,Asia1". For reference, the nucleotide sequence of SEQ ID NO: 93 used as the VP1 region of the FMD Asia1 type is the VP1 region of the FMD Asia1 type contained in pGX9010 provided by INOVIO, USA.

The PLS-FMD-A,O,Asia1 plasmid was prepared in the same manner as in Example 4.

Example 7: Antibody formation effect of novel DNA trivalent vaccine

7.1. DNA vaccination

Prepared in the same manner as in Example 5, but groups 1 to 3 were set as follows.

Group 1 (control)-Mock DNA plasmid

Group 2 (Experimental group)-FMD type A plasmid + PLS-FMD-O + FMD type Asia1 plasmid

Group 3 (Experimental group)-PLS-FMD-A,O,Asia1

7.2. Antibody formation measurement-SPC ELISA assay

As a result of performing the SPC ELISA analysis, as can be seen in FIG. 9, PLS-FMD-O inhibits the response at a significantly higher level even when co-vaccinated with other serotypes, namely A type foot-and-mouth disease vaccine and Asia1 type foot-and-mouth disease vaccine. Figure (PI value) is shown. In addition, even when a single inoculation of the trivalent vaccine showed a significantly high level of response inhibition (PI value).

Therefore, the recombinant O type vaccine according to the present invention has proven useful both as a monovalent vaccine and as a multivalent vaccine.

<110> Plumbline Life Sciences, Inc. <120> VACCINE COMPOSITION FOR FOOT AND MOUTH DISEASE VIRUS <130> DP20153KR <150> KR 10-2019-0077833 <151> 2019-06-28 <150> KR 10-2019-0077839 <151> 2019-06-28 <160> 95 <170> KoPatentIn 3.0 <210> 1 <211> 213 <212> PRT <213> Artificial Sequence <220> <223> FMDV VP1 <400> 1 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 2 <211> 639 <212> DNA <213> Artificial Sequence <220> <223> FMD type O <400> 2 accacctcca ccggagagtc cgccgaccca gtgaccacca ccgtggagaa ctacggcggc 60 gagacacagg tgcagcggcg ccagcacacc gacgtgagct tcatcctgga ccggttcgtg 120 aaggtgaccc caaaggacca gatcaacgtg ctggacctga tgcagacccc tgcacacacc 180 ctggtgggcg ccctgctgag gaccgccacc tactacttcg ccgacctgga ggtggccgtg 240 aagcacgagg gcaacctgac ctgggtgcct aacggagcac cagaggccgc cctggacaac 300 accaccaacc caaccgcata ccacaaggcc cctctgacca ggctggccct gccatacacc 360 gcccctcaca gggtgctggc aaccgtgtac aacggcaact gcaagtacgg agagggcgct 420 gtgaccaacg tgcgcggcga cctgcaggtg ctggcacaga aggcagcaag gaccctgccc 480 accagcttca actacggcgc catcaaggcc accagggtga ccgagctgct gtacagaatg 540 aagcgggccg agacatactg tcccagacca ctgctggcaa tccacccttc ccaggcaagg 600 cacaagcaga agatcgtggc accagtgaag cagctgctg 639 <210> 3 <211> 803 <212> DNA <213> Artificial Sequence <220> <223> PLS-FMD-O <400> 3 tggccagcgc cggcaaggac ttcgacctga gactgccagt ggacgcaagg acccagaggg 60 gaagaaagag gagaagcacc acctccaccg gagagtccgc cgacccagtg accaccaccg 120 tggagaacta cggcggcgag acacaggtgc agcggcgcca gcacaccgac gtgagcttca 180 tcctggaccg gttcgtgaag gtgaccccaa aggaccagat caacgtgctg gacctgatgc 240 agacccctgc acacaccctg gtgggcgccc tgctgaggac cgccacctac tacttcgccg 300 acctggaggt ggccgtgaag cacgagggca acctgacctg ggtgcctaac ggagcaccag 360 aggccgccct ggacaacacc accaacccaa ccgcatacca caaggcccct ctgaccaggc 420 tggccctgcc atacaccgcc cctcacaggg tgctggcaac cgtgtacaac ggcaactgca 480 agtacggaga gggcgctgtg accaacgtgc gcggcgacct gcaggtgctg gcacagaagg 540 cagcaaggac cctgcccacc agcttcaact acggcgccat caaggccacc agggtgaccg 600 agctgctgta cagaatgaag cgggccgaga catactgtcc cagaccactg ctggcaatcc 660 acccttccca ggcaaggcac aagcagaaga tcgtggcacc agtgaagcag ctgctgaggg 720 gacgcaagag gcgctcaacc ctgaacttcg acctcctcaa actggctggc gatgtggaaa 780 gcaatcctgg atgataactc gag 803 <210> 4 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 4 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ser His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Gly Gly Ser Leu Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Pro Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Ala Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 5 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 5 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 6 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 6 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 7 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 7 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Thr Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 8 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 8 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 9 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 9 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 10 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 10 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 11 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 11 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Val Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Asn Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Ala Asn Asn Val 130 135 140 Arg Gly Asp Leu His Val Leu Ala Lys Asn Ala Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Ala Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Asn Thr Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 12 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 12 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Val 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 13 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 13 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 14 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 14 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Ala Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 15 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 15 Thr Thr Ser Thr Gly Glu Thr Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Val 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Ile Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ala Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 16 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 16 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Val Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 17 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 17 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Lys Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Ala Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Gly Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 18 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 18 Thr Thr Ser Thr Gly Glu Thr Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Val 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Ile Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ala Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 19 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 19 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 20 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 20 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 21 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 21 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Ala Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 22 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 22 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 23 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 23 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Glu Asn Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 24 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 24 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Glu Asn Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 25 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 25 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Glu Asn Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 26 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 26 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 27 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 27 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 28 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 28 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 29 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 29 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 30 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 30 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 31 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 31 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Ala Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Val Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Val Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Cys Leu 210 <210> 32 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 32 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Ala Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Val Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Val Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 33 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 33 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 34 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 34 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Val 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 35 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 35 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 36 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 36 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Ile 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Glu Asp Glu Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Val Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Thr Ser Thr Asn Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Arg Lys Thr Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Ala Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Ser Ala Arg His Lys Gln Arg Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 37 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 37 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Pro His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Gly Gly Ser Leu Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 38 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 38 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Ala Pro Gly Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asp Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 39 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 39 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Pro His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Lys Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Gly Gly Ser Leu Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 40 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 40 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Ala Pro Pro His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Ala Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Tyr Lys Tyr Ala Gly Gly Ser Leu Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 41 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 41 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ser His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Gly Gly Ser Leu Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 42 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 42 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ser His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Gly Gly Ser Leu Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 43 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 43 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Ala Pro Pro His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Ala Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Tyr Lys Tyr Ala Gly Gly Ser Leu Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 44 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 44 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Ser Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Pro His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Gly Gly Ser Leu Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Ser Ala Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Ser Leu 210 <210> 45 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 45 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asp Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 46 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 46 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 47 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 47 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Thr Gln Arg Arg Gln His Thr Asp Ile 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Lys Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Thr Asn Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Thr Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Asp Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 48 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 48 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Thr Gln Arg Arg Gln His Thr Asp Ile 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Lys Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Ala Asn Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Thr Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Asp Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Thr Lys Gln Leu Leu 210 <210> 49 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 49 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Thr Gln Arg Arg Gln His Thr Asp Ile 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Lys Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Thr Asn Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Thr Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Asp Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 50 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 50 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Ile 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Glu Asp Glu Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Val Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Thr Ser Thr Asn Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Arg Lys Thr Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Ala Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Ser Ala Arg His Lys Gln Arg Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 51 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 51 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Asn Thr Asn Val 130 135 140 Arg Gly Asp Leu Arg Glu Leu Ala Gln Lys Thr Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Thr Ala Arg His Lys Gln Arg Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 52 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 52 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Asn Thr Asn Val 130 135 140 Arg Gly Asp Leu Arg Glu Leu Ala Gln Lys Ala Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Thr Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 53 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 53 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Asn Thr Asn Val 130 135 140 Arg Gly Asp Leu Arg Glu Leu Ala Gln Lys Ala Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Thr Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 54 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 54 Thr Thr Ser Val Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Val Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asn Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Asn Thr Asp Val 130 135 140 Arg Gly Asp Leu Arg Glu Leu Ala Gln Lys Val Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Thr Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 55 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 55 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 56 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 56 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Ser Asn Val Pro Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 57 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 57 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 58 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 58 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 59 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 59 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 60 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 60 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Arg Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 61 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 61 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Arg Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Gln Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 62 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 62 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu His Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Ala Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Asn Lys Tyr Gly Asp Ala Ser Ala Asn Asn Ile 130 135 140 Arg Gly Asp Leu His Val Leu Ala Lys Asn Ala Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Ala Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Thr Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 63 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 63 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Val 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Ala Ser Ala Asn Asn Val 130 135 140 Arg Gly Asp Leu His Val Leu Ala Lys Asn Ala Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Val Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile Gln Pro Ser Thr Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 64 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 64 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 65 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 65 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 66 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 66 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Ala Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ala Phe Ile Leu Asp Arg Phe Val Lys Val Lys Pro Gln Glu Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Ile Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Leu Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Glu Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Ser Asn Lys Tyr Gly Asp Thr Ser Ala Asn Asn Val 130 135 140 Arg Gly Asp Leu His Val Leu Ala Lys Asn Ala Glu Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Thr Gln Pro Ser Thr Asp Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Ala Lys Gln Leu Leu 210 <210> 67 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 67 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 68 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 68 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 69 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 69 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 70 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 70 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 71 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 71 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 72 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 72 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 73 <211> 211 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 73 Thr Thr Ser Ala Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ser His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asp Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Glu Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Ala Glu Gly Ser Leu Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Pro Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Val His Pro Asp Gln Ser Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln 210 <210> 74 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 74 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 75 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 75 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 76 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 76 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Ala Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Arg Tyr Gly Ala Ser Pro Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Ser Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 77 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 77 Thr Thr Ser Thr Gly Glu Tyr Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 78 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 78 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 79 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 79 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 80 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 80 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 81 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 81 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Leu Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 82 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 82 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Leu Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 83 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 83 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Thr 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 84 <211> 213 <212> PRT <213> Unknown <220> <223> FMDV VP1 <400> 84 Thr Thr Ser Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Val Gln Arg Arg Gln His Thr Asp Val 20 25 30 Ser Phe Ile Leu Asp Arg Phe Val Lys Val Thr Pro Lys Asp Gln Ile 35 40 45 Asn Val Leu Asp Leu Met Gln Thr Pro Ala His Thr Leu Val Gly Ala 50 55 60 Leu Leu Arg Thr Ala Thr Tyr Tyr Phe Ala Asp Leu Glu Val Ala Val 65 70 75 80 Lys His Glu Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Thr Asn Pro Thr Ala Tyr His Lys Ala Pro Leu 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Asn Cys Lys Tyr Gly Glu Gly Ala Val Thr Asn Val 130 135 140 Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala Arg Thr Leu Pro 145 150 155 160 Thr Ser Phe Asn Tyr Gly Ala Ile Lys Ala Thr Arg Val Thr Glu Leu 165 170 175 Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu 180 185 190 Ala Ile His Pro Glu Gln Ala Arg His Lys Gln Lys Ile Val Ala Pro 195 200 205 Val Lys Gln Leu Leu 210 <210> 85 <211> 212 <212> PRT <213> Artificial Sequence <220> <223> FMDV A VP1 <400> 85 Thr Thr Ala Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Ala Gln Arg Arg His His Thr Asp Val 20 25 30 Gly Phe Leu Met Asp Arg Phe Val Gln Ile Lys Pro Val Ser Pro Thr 35 40 45 His Val Ile Asp Leu Met Gln Thr His Gln His Gly Leu Val Gly Ala 50 55 60 Met Leu Arg Ala Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Ile Val Val 65 70 75 80 Asn His Thr Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asn Asn Thr Ser Asn Pro Thr Ala Tyr His Lys Ala Pro Phe 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Ser Gly Thr Ser Lys Tyr Ser Thr Pro Gln Thr Arg Arg Gly 130 135 140 Asp Leu Gly Pro Leu Ala Ala Arg Leu Ala Ala Gln Leu Pro Ala Ser 145 150 155 160 Phe Asn Phe Gly Ala Ile Arg Ala Thr Glu Ile Gln Glu Leu Leu Val 165 170 175 Arg Met Lys Arg Ala Glu Leu Tyr Cys Pro Arg Pro Leu Leu Ala Val 180 185 190 Glu Val Ser Ser Gln Asp Arg His Lys Gln Lys Ile Ile Ala Pro Ala 195 200 205 Lys Gln Leu Leu 210 <210> 86 <211> 212 <212> PRT <213> Artificial Sequence <220> <223> FMDV A VP1 <400> 86 Thr Thr Ala Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu 1 5 10 15 Asn Tyr Gly Gly Glu Thr Gln Ala Gln Arg Arg His His Thr Asp Val 20 25 30 Ser Phe Ile Met Asp Arg Phe Val Arg Ile Lys Pro Val Ser Pro Thr 35 40 45 His Val Ile Asp Leu Met Gln Thr His Gln His Gly Leu Val Gly Ala 50 55 60 Met Leu Arg Ala Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Ile Val Val 65 70 75 80 Asn His Thr Gly Asn Leu Thr Trp Val Pro Asn Gly Ala Pro Glu Ala 85 90 95 Ala Leu Asp Asn Thr Ser Asn Pro Thr Ala Tyr His Lys Ala Pro Phe 100 105 110 Thr Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr 115 120 125 Val Tyr Asn Gly Thr Ser Lys Tyr Ser Thr Pro Gly Ala Arg Arg Gly 130 135 140 Asp Leu Gly Ser Leu Ala Ala Arg Leu Ala Ala Gln Leu Pro Ala Ser 145 150 155 160 Phe Asn Phe Gly Ala Ile Arg Ala Thr Glu Ile Gln Glu Leu Leu Val 165 170 175 Arg Met Lys Arg Ala Glu Leu Tyr Cys Pro Arg Pro Leu Leu Ala Val 180 185 190 Glu Val Leu Ser Gln Asp Arg His Lys Gln Lys Ile Ile Ala Pro Ala 195 200 205 Lys Gln Leu Leu 210 <210> 87 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> FMDV A VP4-VP2-VP3 <400> 87 Asp Lys Lys Thr Glu Glu Thr Thr Leu Leu Glu Asp Arg Ile Leu Thr 1 5 10 15 Thr Arg Asn Gly His Thr Thr Ser Thr Thr Gln Ser Ser Val Gly Val 20 25 30 Thr His Gly Tyr Ser Thr Glu Glu Asp His Val Ala Gly Pro Asn Thr 35 40 45 Ser Gly Leu Glu Thr Arg Val Val Gln Ala Glu Arg Phe Tyr Lys Lys 50 55 60 Tyr Leu Phe Asp Trp Thr Thr Asp Lys Ala Phe Gly His Leu Glu Lys 65 70 75 80 Leu Glu Leu Pro Ser Asp His His Gly Val Phe Gly His Leu Val Asp 85 90 95 Ser Tyr Ala Tyr Met Arg Asn Gly Trp Asp Val Glu Val Ser Ala Val 100 105 110 Gly Asn Gln Phe Asn Gly Gly Cys Leu Leu Val Ala Met Val Pro Glu 115 120 125 Trp Lys Glu Phe Asp Thr Arg Glu Lys Tyr Gln Leu Thr Leu Phe Pro 130 135 140 His Gln Phe Ile Ser Pro Arg Thr Asn Met Thr Ala His Ile Thr Val 145 150 155 160 Pro Tyr Leu Gly Val Asn Arg Tyr Asp Gln Tyr Lys Lys His Lys Pro 165 170 175 Trp Thr Leu Val Val Met Val Val Ser Pro Leu Thr Val Asn Asn Thr 180 185 190 Ser Ala Ala Gln Ile Lys Val Tyr Ala Asn Ile Ala Pro Thr Tyr Val 195 200 205 His Val Ala Gly Glu Leu Pro Ser Lys Glu Arg Gly Arg Lys Arg Arg 210 215 220 Ser Gly Ile Phe Pro Val Ala Cys Ala Asp Gly Tyr Gly Gly Leu Val 225 230 235 240 Thr Thr Asp Pro Lys Thr Ala Asp Pro Ala Tyr Gly Lys Val Tyr Asn 245 250 255 Pro Pro Arg Thr Asn Tyr Pro Gly Arg Phe Thr Asn Leu Leu Asp Val 260 265 270 Ala Glu Ala Cys Pro Thr Phe Leu Cys Phe Asp Asp Gly Lys Pro Tyr 275 280 285 Val Thr Thr Arg Thr Asp Asp Thr Arg Leu Leu Ala Lys Phe Asp Leu 290 295 300 Ser Leu Ala Ala Lys His Met Ser Asn Thr Tyr Leu Ser Gly Ile Ala 305 310 315 320 Gln Tyr Tyr Thr Gln Tyr Ser Gly Thr Ile Asn Leu His Phe Met Phe 325 330 335 Thr Gly Ser Thr Asp Ser Lys Ala Arg Tyr Met Val Ala Tyr Ile Pro 340 345 350 Pro Gly Val Glu Thr Pro Pro Asp Thr Pro Glu Arg Ala Ala His Cys 355 360 365 Ile His Ala Glu Trp Asp Thr Gly Leu Asn Ser Lys Phe Thr Phe Ser 370 375 380 Ile Pro Tyr Val Ser Ala Ala Asp Tyr Ala Tyr Thr Ala Ser Asp Thr 385 390 395 400 Ala Glu Thr Ile Asn Val Gln Gly Trp Val Cys Ile Tyr Gln Ile Thr 405 410 415 His Gly Lys Ala Glu Asn Asp Thr Leu Val Val Ser Val Ser Ala Gly 420 425 430 Lys Asp Phe Glu Leu Arg Leu Pro Ile Asp Pro Arg Gln Gln 435 440 445 <210> 88 <211> 636 <212> DNA <213> Artificial Sequence <220> <223> FMDV A VP1 <400> 88 accaccgcca ccggggaatc agcagaccct gtcacaacca ccgttgagaa ctacggtggc 60 gagacacaag cacagcggcg tcaccacacc gacgtcggct tcttaatgga caggttcgtg 120 cagatcaagc ctgtgagccc cacacatgtc attgacctca tgcagacaca ccaacacggg 180 ctggtgggcg ccatgttgcg cgcggccacc tactactttt ctgatcttga gattgtggtg 240 aaccacacgg gtaacctaac gtgggtaccc aatggagcac ccgaggcagc actgaacaac 300 acgagcaacc ccactgctta ccacaaagcg ccgttcacga ggcttgcgct cccctacacc 360 gcgccacacc gcgtgctggc aactgtgtac agcgggacga gcaagtactc cacacctcaa 420 acacggcgag gtgacctggg tcctctcgcg gcgaggctcg ctgcacagct ccctgcctcc 480 ttcaacttcg gtgcaattcg ggccacggag atccaagaac tccttgtgcg catgaagcgc 540 gccgagctct actgccccag gccactgttg gcggtggagg tgtcgtcgca agacagacac 600 aagcagaaaa tcattgcccc tgcaaaacaa ctcctg 636 <210> 89 <211> 636 <212> DNA <213> Artificial Sequence <220> <223> FMDV A VP1 DNA porcine codon optimization <400> 89 acaacagcca caggagaatc cgccgaccca gtgacaacca ccgtggagaa ctacggagga 60 gagacacagg ctcagcgccg gcaccacacc gacgtgggct tcctgatgga caggttcgtg 120 cagatcaagc ccgtgagccc aacccacgtg atcgacctga tgcagaccca ccagcacggc 180 ctggtgggag ctatgctgag ggctgccacc tactacttct ccgacctgga gatcgtggtg 240 aaccacaccg gaaacctgac ctgggtgcca aacggagctc cagaggccgc cctgaacaac 300 accagcaacc ccaccgccta ccacaaggct ccattcacca ggctggccct gccatacacc 360 gctccacacc gggtgctggc taccgtgtac tccggcacca gcaagtactc caccccacag 420 accaggagag gcgacctggg accactggct gctaggctgg ctgctcagct gccagcctcc 480 ttcaacttcg gagctatcag ggctaccgag atccaggagc tgctggtgag gatgaagaga 540 gccgagctgt actgccccag gccactgctg gctgtggagg tgtccagcca ggacagacac 600 aagcagaaga tcatcgcccc agccaagcag ctgctg 636 <210> 90 <211> 636 <212> DNA <213> Artificial Sequence <220> <223> FMDV A VP1 <400> 90 acaacagcca caggagaatc cgccgaccca gtgacaacca ccgtggagaa ctacggagga 60 gagacacagg ctcagcgccg gcaccacacc gacgtgggct tcctgatgga caggttcgtg 120 cagatcaagc ccgtgagccc aacccacgtg atcgacctga tgcagaccca ccagcacggc 180 ctggtgggag ctatgctgag ggctgccacc tactacttct ccgacctgga gatcgtggtg 240 aaccacaccg gaaacctgac ctgggtgcca aacggagctc cagaggccgc cctgaacaac 300 accagcaacc ccaccgccta ccacaaggct ccattcacca ggctggccct gccatacacc 360 gctccacacc gggtgctggc taccgtgtac tccggcacca gcaagtactc caccccacag 420 accaggagag gcgacctggg accactggct gctaggctgg ctgctcagct gccagcctcc 480 ttcaacttcg gagctatcag ggctaccgag atccaggagc tgctggtgag gatgaagaga 540 gccgagctgt actgccccag gccactgctg gctgtggagg tgtccagcca ggacagacac 600 aagcagaaga tcatcgcccc agccaagcag ctgctg 636 <210> 91 <211> 636 <212> DNA <213> Artificial Sequence <220> <223> FMDV A VP4-VP2-VP3 <400> 91 acaacagcca caggagaatc cgccgaccca gtgacaacca ccgtggagaa ctacggagga 60 gagacacagg ctcagcgccg gcaccacacc gacgtgggct tcctgatgga caggttcgtg 120 cagatcaagc ccgtgagccc aacccacgtg atcgacctga tgcagaccca ccagcacggc 180 ctggtgggag ctatgctgag ggctgccacc tactacttct ccgacctgga gatcgtggtg 240 aaccacaccg gaaacctgac ctgggtgcca aacggagctc cagaggccgc cctgaacaac 300 accagcaacc ccaccgccta ccacaaggct ccattcacca ggctggccct gccatacacc 360 gctccacacc gggtgctggc taccgtgtac tccggcacca gcaagtactc caccccacag 420 accaggagag gcgacctggg accactggct gctaggctgg ctgctcagct gccagcctcc 480 ttcaacttcg gagctatcag ggctaccgag atccaggagc tgctggtgag gatgaagaga 540 gccgagctgt actgccccag gccactgctg gctgtggagg tgtccagcca ggacagacac 600 aagcagaaga tcatcgcccc agccaagcag ctgctg 636 <210> 92 <211> 2400 <212> DNA <213> Artificial Sequence <220> <223> FMDV A VP4-VP2-VP3-VP1 <400> 92 gccaccatgg attggacatg gattctgttc ctggtggctg ctgctactag agtgcattca 60 ggggccggac agtcttcacc cgcaaccgga tcacagaacc agagtggaaa taccgggagc 120 atcattaaca attactatat gcagcagtac cagaacagca tggacacaca gctgggggat 180 aacgccatca gcggcggcag caatgagggc tccacagata ccacatctac tcacactacc 240 aatacccaga acaatgactg gttctctaaa ctggcaagct ccgccttcac cggcctcttt 300 ggagctctgc tcgcaagggg aagaaagagg agaagcgata agaaaacaga ggaaaccacc 360 ctgctggagg acagaatcct gaccacaaga aacgggcaca ctaccagcac aactcagtct 420 tcagtgggcg tcacacacgg atactcaact gaggaagacc atgtggccgg gccaaatacc 480 agtggcctgg agacacgagt ggtccaggct gaaaggttct acaagaaata tctgtttgac 540 tggaccacag ataaggcctt cggccacctg gagaaactgg aactcccctc agaccaccac 600 ggcgtgttcg gccatctggt cgatagctac gcctatatga gaaacggatg ggacgtggag 660 gtctccgctg tgggcaacca gttcaatggc ggatgcctgc tcgtggctat ggtgcccgag 720 tggaaggaat ttgataccag ggaaaaatac cagctgacac tcttcccaca ccagtttatc 780 tctcctagaa ctaacatgac cgcccatatt accgtgcctt atctgggcgt caatcggtac 840 gaccagtata agaaacacaa accttggacc ctggtggtca tggtggtcag tcccctcaca 900 gtgaacaata ctagcgccgc tcagatcaag gtctacgcca acattgctcc aacctatgtg 960 cacgtcgcag gagagctgcc ttccaaggaa cggggacgca aacggcgctc tgggatcttc 1020 ccagtggcat gtgctgacgg atacggaggg ctggtcacta ccgaccctaa gaccgcagat 1080 cccgcctacg gaaaagtgta taacccaccc aggactaatt acccagggcg gttcaccaac 1140 ctgctcgatg tggcagaggc ctgccccacc ttcctgtgct ttgacgatgg caagccatac 1200 gtgacaactc ggacagacga tactcgcctg ctcgccaagt ttgacctgag cctcgcagcc 1260 aaacacatgt caaacaccta cctgagtgga atcgcccagt actatactca gtattccggg 1320 accattaatc tgcatttcat gtttaccggc tctacagact caaaggctcg ctacatggtg 1380 gcatatatcc ctcccggcgt cgagacccca cctgatacac ctgaaagggc tgcacactgc 1440 atccatgccg agtgggacac aggactgaac agcaagttca ctttttccat tccctacgtg 1500 tctgccgctg actacgctta taccgcatcc gatactgccg aaaccattaa cgtgcaggga 1560 tgggtctgta tctaccagat tactcacggg aaagccgaga atgacaccct ggtggtctcc 1620 gtgtctgctg gcaaggactt cgaactcaga ctccccattg acccaagaca gcagagaggc 1680 agaaaaagac gcagcacaac agccacagga gaatccgccg acccagtgac aaccaccgtg 1740 gagaactacg gaggagagac acaggctcag cgccggcacc acaccgacgt gggcttcctg 1800 atggacaggt tcgtgcagat caagcccgtg agcccaaccc acgtgatcga cctgatgcag 1860 acccaccagc acggcctggt gggagctatg ctgagggctg ccacctacta cttctccgac 1920 ctggagatcg tggtgaacca caccggaaac ctgacctggg tgccaaacgg agctccagag 1980 gccgccctga acaacaccag caaccccacc gcctaccaca aggctccatt caccaggctg 2040 gccctgccat acaccgctcc acaccgggtg ctggctaccg tgtactccgg caccagcaag 2100 tactccaccc cacagaccag gagaggcgac ctgggaccac tggctgctag gctggctgct 2160 cagctgccag cctccttcaa cttcggagct atcagggcta ccgagatcca ggagctgctg 2220 gtgaggatga agagagccga gctgtactgc cccaggccac tgctggctgt ggaggtgtcc 2280 agccaggaca gacacaagca gaagatcatc gccccagcca agcagctgct gcgcggccgg 2340 aaacgacgct ctaattttga cctcctgaaa ctggctggcg atgtggaatc taaccctggc 2400 2400 <210> 93 <211> 633 <212> DNA <213> Artificial Sequence <220> <223> FMDV Asia1 type VP1 <400> 93 actaccacaa ctggggaatc agccgaccca gtcaccacaa ctgtggagaa ctacggcgga 60 gaaacccaga cagcaagacg gctgcacacc gacgtggcct tcatcctcga tcgctttgtg 120 aagctgacag cccccaaaaa tatccagact ctggacctca tgcagattcc atcccataca 180 ctggtgggcg cactgctcag gagtgccact tactatttca gcgacctgga ggtcgctctc 240 gtgcacactg gaccagtcac ctgggtgcct aacggagcac caaaggatgc tctgaacaat 300 cagaccaatc caacagccta ccagaaacag cctatcacca ggctggctct cccatataca 360 gcacctcaca gagtcctggc taccgtgtac aacggaaaga ccgcctacgg cgagaccaca 420 agccgccgag gcgacatggc agccctggcc cagcggctct ccgctcgcct gcccacatct 480 ttcaattacg gagcagtgaa ggccgatact atcaccgagc tgctcattag gatgaaaaga 540 gccgaaacct attgccccag gccactgctc gctctggaca ctacccagga taggagaaag 600 caggagatca ttgccccaga aaaacaggtg ctg 633 <210> 94 <211> 2262 <212> DNA <213> Artificial Sequence <220> <223> FMDV Asia1 type VP4-VP2-VP3-VP1 <400> 94 ggggccggac agtcttcacc tgctactggg agccagaacc agagcggaaa tacagggtcc 60 atcattaaca attactatat gcagcagtac cagaacagca tggacaccca gctgggcgat 120 aacgccatct ccggcggatc taatgaggga tctactgaca ccacatcaac acacactaac 180 aatacccaga acaatgattg gttcagtaga ctcgccagct ccgctttctc tggactgttt 240 ggagcactgc tcgcccgggg ccgcaagagg agatccgaca agaaaaccga ggaaaccacc 300 ctgctggagg atcgaatcct gacaactagg aacggacata ccacaagcac tacccagtct 360 tcagtgggag tcacctacgg gtatgctgtc gcagaagacg ccgtgagtgg gcccaacaca 420 agcggcctgg agactagagt gcagcaggct gaacggttct ttaagaaaca cctcttcgat 480 tggacaccta atctggcctt tggccattgc tactatctgg agctccccac cgaacacaag 540 ggggtgtacg gctcactgat ggggagttac gcatatatgc ggaacggatg ggacatcgag 600 gtgaccgcag tcggaaacca gttcaatggc ggatgtctgc tcgtggctct ggtccctgag 660 ctgaaggaac tcgatacaag gcagaaatac cagctgactc tcttccctca tcagtttatt 720 aaccccagaa caaatatgac tgcccacatc aacgtgccct acgtcggcat taatcggtac 780 gaccagtatg ccctccataa gccttggacc ctggtggtca tggtggtcgc tcccctgacc 840 gtgaagacag gagggtccga gcagatcaaa gtgtacatga acgccgctcc aacctatgtg 900 cacgtcgccg gcgagctgcc ttcaaaggaa cgaggcagga aacggcgctc tggaattgtg 960 ccagtcgcat gcgctgacgg atacggaaac atggtgacaa ctgaccccaa gaccgccgat 1020 ccagtctatg gaaaagtgtt caacccaccc aggaccaatc tccctgggcg attcacaaac 1080 tttctggatg tggcagaggc ctgtcccaca ttcctgcggt ttggggaagt gccattcgtc 1140 aagaccgtga acagcggcga ccgactgctc gccaaatttg acgtgagcct ggccgccggc 1200 cacatgagta acacctacct ggctggactc gcacagtact atacccagta tagcgggaca 1260 atgaatgtgc acttcatgtt tactggccca accgacgcta aggcaagata catggtcgcc 1320 tatgtgcctc ccgggatgac accacctact gaccctgagc acgctgcaca ttgcatccac 1380 agcgaatggg atactggcct caactccaaa ttcacctttt ctattcccta cctgtcagcc 1440 gctgactacg cctatacagc cagcgatgtg gccgagacca catccgtcca gggatgggtg 1500 tgcatctacc agattaccca cggcaaggct gagggagacg cactggtggt gagcgtgagc 1560 gccgggaaag acttcgaatt tcggctgccc gtggatgcac gccagcagag aggacggaag 1620 cgaaggtcta ctaccacaac tggggaatca gccgacccag tcaccacaac tgtggagaac 1680 tacggcggag aaacccagac agcaagacgg ctgcacaccg acgtggcctt catcctcgat 1740 cgctttgtga agctgacagc ccccaaaaat atccagactc tggacctcat gcagattcca 1800 tcccatacac tggtgggcgc actgctcagg agtgccactt actatttcag cgacctggag 1860 gtcgctctcg tgcacactgg accagtcacc tgggtgccta acggagcacc aaaggatgct 1920 ctgaacaatc agaccaatcc aacagcctac cagaaacagc ctatcaccag gctggctctc 1980 ccatatacag cacctcacag agtcctggct accgtgtaca acggaaagac cgcctacggc 2040 gagaccacaa gccgccgagg cgacatggca gccctggccc agcggctctc cgctcgcctg 2100 cccacatctt tcaattacgg agcagtgaag gccgatacta tcaccgagct gctcattagg 2160 atgaaaagag ccgaaaccta ttgccccagg ccactgctcg ctctggacac tacccaggat 2220 aggagaaagc aggagatcat tgccccagaa aaacaggtgc tg 2262 <210> 95 <211> 754 <212> PRT <213> Artificial Sequence <220> <223> FMDV Asia1 type VP4-VP2-VP3-VP1 <400> 95 Gly Ala Gly Gln Ser Ser Pro Ala Thr Gly Ser Gln Asn Gln Ser Gly 1 5 10 15 Asn Thr Gly Ser Ile Ile Asn Asn Tyr Tyr Met Gln Gln Tyr Gln Asn 20 25 30 Ser Met Asp Thr Gln Leu Gly Asp Asn Ala Ile Ser Gly Gly Ser Asn 35 40 45 Glu Gly Ser Thr Asp Thr Thr Ser Thr His Thr Asn Asn Thr Gln Asn 50 55 60 Asn Asp Trp Phe Ser Arg Leu Ala Ser Ser Ala Phe Ser Gly Leu Phe 65 70 75 80 Gly Ala Leu Leu Ala Arg Gly Arg Lys Arg Arg Ser Asp Lys Lys Thr 85 90 95 Glu Glu Thr Thr Leu Leu Glu Asp Arg Ile Leu Thr Thr Arg Asn Gly 100 105 110 His Thr Thr Ser Thr Thr Gln Ser Ser Ser Val Gly Val Thr Tyr Gly Tyr 115 120 125 Ala Val Ala Glu Asp Ala Val Ser Gly Pro Asn Thr Ser Gly Leu Glu 130 135 140 Thr Arg Val Gln Gln Ala Glu Arg Phe Phe Lys Lys His Leu Phe Asp 145 150 155 160 Trp Thr Pro Asn Leu Ala Phe Gly His Cys Tyr Tyr Leu Glu Leu Pro 165 170 175 Thr Glu His Lys Gly Val Tyr Gly Ser Leu Met Gly Ser Tyr Ala Tyr 180 185 190 Met Arg Asn Gly Trp Asp Ile Glu Val Thr Ala Val Gly Asn Gln Phe 195 200 205 Asn Gly Gly Cys Leu Leu Val Ala Leu Val Pro Glu Leu Lys Glu Leu 210 215 220 Asp Thr Arg Gln Lys Tyr Gln Leu Thr Leu Phe Pro His Gln Phe Ile 225 230 235 240 Asn Pro Arg Thr Asn Met Thr Ala His Ile Asn Val Pro Tyr Val Gly 245 250 255 Ile Asn Arg Tyr Asp Gln Tyr Ala Leu His Lys Pro Trp Thr Leu Val 260 265 270 Val Met Val Val Ala Pro Leu Thr Val Lys Thr Gly Gly Ser Glu Gln 275 280 285 Ile Lys Val Tyr Met Asn Ala Ala Pro Thr Tyr Val His Val Ala Gly 290 295 300 Glu Leu Pro Ser Lys Glu Arg Gly Arg Lys Arg Arg Ser Gly Ile Val 305 310 315 320 Pro Val Ala Cys Ala Asp Gly Tyr Gly Asn Met Val Thr Thr Asp Pro 325 330 335 Lys Thr Ala Asp Pro Val Tyr Gly Lys Val Phe Asn Pro Pro Arg Thr 340 345 350 Asn Leu Pro Gly Arg Phe Thr Asn Phe Leu Asp Val Ala Glu Ala Cys 355 360 365 Pro Thr Phe Leu Arg Phe Gly Glu Val Pro Phe Val Lys Thr Val Asn 370 375 380 Ser Gly Asp Arg Leu Leu Ala Lys Phe Asp Val Ser Leu Ala Ala Gly 385 390 395 400 His Met Ser Asn Thr Tyr Leu Ala Gly Leu Ala Gln Tyr Tyr Thr Gln 405 410 415 Tyr Ser Gly Thr Met Asn Val His Phe Met Phe Thr Gly Pro Thr Asp 420 425 430 Ala Lys Ala Arg Tyr Met Val Ala Tyr Val Pro Pro Gly Met Thr Pro 435 440 445 Pro Thr Asp Pro Glu His Ala Ala His Cys Ile His Ser Glu Trp Asp 450 455 460 Thr Gly Leu Asn Ser Lys Phe Thr Phe Ser Ile Pro Tyr Leu Ser Ala 465 470 475 480 Ala Asp Tyr Ala Tyr Thr Ala Ser Asp Val Ala Glu Thr Thr Ser Val 485 490 495 Gln Gly Trp Val Cys Ile Tyr Gln Ile Thr His Gly Lys Ala Glu Gly 500 505 510 Asp Ala Leu Val Val Ser Val Ser Ala Gly Lys Asp Phe Glu Phe Arg 515 520 525 Leu Pro Val Asp Ala Arg Gln Gln Arg Gly Arg Lys Arg Arg Ser Thr 530 535 540 Thr Thr Thr Gly Glu Ser Ala Asp Pro Val Thr Thr Thr Val Glu Asn 545 550 555 560 Tyr Gly Gly Glu Thr Gln Thr Ala Arg Arg Leu His Thr Asp Val Ala 565 570 575 Phe Ile Leu Asp Arg Phe Val Lys Leu Thr Ala Pro Lys Asn Ile Gln 580 585 590 Thr Leu Asp Leu Met Gln Ile Pro Ser His Thr Leu Val Gly Ala Leu 595 600 605 Leu Arg Ser Ala Thr Tyr Tyr Phe Ser Asp Leu Glu Val Ala Leu Val 610 615 620 His Thr Gly Pro Val Thr Trp Val Pro Asn Gly Ala Pro Lys Asp Ala 625 630 635 640 Leu Asn Asn Gln Thr Asn Pro Thr Ala Tyr Gln Lys Gln Pro Ile Thr 645 650 655 Arg Leu Ala Leu Pro Tyr Thr Ala Pro His Arg Val Leu Ala Thr Val 660 665 670 Tyr Asn Gly Lys Thr Ala Tyr Gly Glu Thr Thr Ser Arg Arg Gly Asp 675 680 685 Met Ala Ala Leu Ala Gln Arg Leu Ser Ala Arg Leu Pro Thr Ser Phe 690 695 700 Asn Tyr Gly Ala Val Lys Ala Asp Thr Ile Thr Glu Leu Leu Ile Arg 705 710 715 720 Met Lys Arg Ala Glu Thr Tyr Cys Pro Arg Pro Leu Leu Ala Leu Asp 725 730 735 Thr Thr Gln Asp Arg Arg Lys Gln Glu Ile Ile Ala Pro Glu Lys Gln 740 745 750 Val Leu

Claims (17)

A polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% homology thereto. The amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 90% or more homology thereto; And at least one of the amino acid sequences of VP2, VP3 and VP4 proteins of foot-and-mouth disease virus. The method of claim 2,
The VP2, VP3 and VP4 proteins of the foot-and-mouth disease virus are derived from O-type foot-and-mouth disease virus. A polynucleotide comprising the amino acid sequence of SEQ ID NO: 1 or a base sequence encoding an amino acid sequence having 90% or more homology thereto, or a base sequence of SEQ ID NO: 2 or a base sequence having 90% or more homology thereto. A plasmid comprising the polynucleotide of claim 4. The method of claim 5,
Plasmid comprising the nucleotide sequence of SEQ ID NO: 3. The method of claim 5,
A plasmid further comprising a base sequence encoding at least one of VP2, VP3 and VP4 proteins of foot-and-mouth disease virus. The method of claim 7,
The VP2, VP3 and VP4 proteins of the foot-and-mouth disease virus are derived from O-type foot-and-mouth disease virus. A foot-and-mouth disease vaccine composition comprising the polypeptide of any one of claims 1 to 3, the polynucleotide of claim 4, or the plasmid of any one of claims 5 to 8. The method of claim 9,
The vaccine is a monovalent vaccine or a foot-and-mouth disease vaccine composition, characterized in that the multivalent vaccine. The method of claim 9,
The polynucleotide further comprises an amino acid sequence of the VP1 protein of at least one foot-and-mouth disease virus selected from the group consisting of A type, C type, SAT1 type, SAT2 type, SAT3 type and Asia1 type. The method of claim 9,
The polynucleotide is a foot-and-mouth disease vaccine, characterized in that it further comprises amino acid sequences of VP2, VP3 and VP4 proteins of at least one foot-and-mouth disease virus selected from the group consisting of A type, C type, SAT1 type, SAT2 type, SAT3 type and Asia1 type Composition. A method for generating an immune response against foot-and-mouth disease virus in a subject, comprising administering the vaccine composition of claim 9 to the subject. The method of claim 13,
The method of claim 1, wherein the administration is by electroporation. A method for preventing foot-and-mouth disease, comprising administering the vaccine composition of claim 9 to a subject. The method of claim 15,
The method of claim 1, wherein the administration is by electroporation. A pharmaceutical composition for preventing foot-and-mouth disease, comprising the polypeptide of any one of claims 1 to 3, the polynucleotide of claim 4, or the plasmid of any one of claims 5 to 8.

Images